A meningitis vaccine has been shown to protect against gonorrhoea, making it the first drug to prevent sexually transmitted disease that is increasingly becoming resistant to antibiotics, scientists said today. Last week, the World Health Organization (WHO) warned that antibiotic resistance is making gonorrhoea "much harder and sometimes impossible" to treat and new drugs need to be developed to treat the disease. Each year, an estimated 78 million people are infected with gonorrhoea - which can infect the genitals, rectum, and throat. The new study of 15,000 young people, published in the Lancet, showed infections were cut by about a third. The vaccine, originally developed to stop an outbreak of meningitis B, was given to about a million adolescents in New Zealand between 2004 and 2006. Researchers at the University of Auckland in the New Zealand analysed data from sexual health clinics and found gonorrhoea cases had fallen 31 per cent in those vaccinated. The bacterium that causes meningitis, Neisseria meningitidis, is a very close relative of the species that causes gonorrhoea - Neisseria gonorrhoeae, the 'BBC News' reported. However, the vaccine - known as MeNZB - is no longer commercially available.
Many of its components are also in a new meningitis B jab - called 4CMenB. Researchers found that the meningitis B jab was giving "cross-protection" against gonorrhoea. The protection seemed to last about two years. "This is the first time a vaccine has shown any protection against gonorrhoea," said Helen Petousis-Harris, from University of Auckland. "At the moment, the mechanism behind this immune response is unknown, but our findings could inform future vaccine development," Petousis-Harris said.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)